Latest Stories
3 Reasons to Avoid MD and 1 Stock to Buy Instead
Pediatrix Medical Group has been on fire lately. In the past six months alone, the company’s stock price has rocketed 76.8%, reaching $22.67 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
2 Reasons to Like IBTA and 1 to Stay Skeptical
Ibotta’s stock price has taken a beating over the past six months, shedding 37.8% of its value and falling to $22.96 per share. This may have investors wondering how to approach the situation.
3 Big Reasons to Love AMD (AMD)
What a fantastic six months it’s been for AMD. Shares of the company have skyrocketed 43.9%, hitting $230.32. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
3 Reasons to Sell AFL and 1 Stock to Buy Instead
Aflac trades at $110.01 per share and has stayed right on track with the overall market, gaining 8.4% over the last six months. At the same time, the S&P 500 has returned 10.6%.
3 Reasons to Avoid CACC and 1 Stock to Buy Instead
Over the last six months, Credit Acceptance’s shares have sunk to $473.35, producing a disappointing 5.7% loss - a stark contrast to the S&P 500’s 10.6% gain. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
3 Reasons JLL is Risky and 1 Stock to Buy Instead
The past six months have been a windfall for JLL’s shareholders. The company’s stock price has jumped 41.3%, setting a new 52-week high of $354.03 per share. This run-up might have investors contemplating their next move.
3 Reasons to Avoid CNA and 1 Stock to Buy Instead
CNA Financial trades at $46.42 and has moved in lockstep with the market. Its shares have returned 6.1% over the last six months while the S&P 500 has gained 10.6%.
3 Reasons AEO is Risky and 1 Stock to Buy Instead
What a time it’s been for American Eagle. In the past six months alone, the company’s stock price has increased by a massive 164%, reaching $25.96 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Medpace (MEDP): Buy, Sell, or Hold Post Q3 Earnings?
What a time it’s been for Medpace. In the past six months alone, the company’s stock price has increased by a massive 96.1%, reaching $617.27 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Amtech (ASYS): Buy, Sell, or Hold Post Q3 Earnings?
The past six months have been a windfall for Amtech’s shareholders. The company’s stock price has jumped 212%, hitting $14.10 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.